Gene anomaly can predict behavior of prostate cancer

Share this article:

The findings of a recent analysis indicate that a specific genomic abnormality found in either benign or malignant prostate tissues is predictive of the clinical outcome of prostate cancer.

As pathologist Jian-Hua Luo, MD, PhD, of the University of Pittsburgh (Pennsylvania) School of Medicine, and colleagues state in The American Journal of Pathology, the prediction of prostate cancer clinical outcome remains a major challenge, even with improved early detection by prostate-specific antigen (PSA) monitoring. But the group has discovered that a genetic abnormality known as copy number variation (CNV) in prostate tumors, in benign prostate tissue adjacent to the tumor (AT), and in the blood of men with prostate cancer can predict whether a patient will experience a relapse, and whether the relapse will be aggressive or indolent. CNVs are large areas of the genome with either duplicated or missing sections of DNA.

Luo's team performed a comprehensive genome analysis on a total of 238 samples obtained from men undergoing radical prostatectomy: 104 tumor samples, 49 matched AT, and 85 matched blood. The investigators also tested three commercially available prostate cancer cell lines to validate the results.

Using gene-specific CNV from the tumor samples, the genome model correctly predicted 73% of the cases that would relapse and 75% of the cases that would show short PSA doubling time (less than 4 months). Using median-sized CNV from the tumor, those rates rose to 75% and 80%, respectively.

The gene-specific CNV model from AT correctly predicted 67% of the cases for relapse and 77% of the cases for short PSA doubling time. Median-sized CNV from the blood correctly predicted 81% and 69% of those cases, respectively.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Irinotecan promising in some patients with stage III colon cancer

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to recent research.

Genetic sequence of rare kidney cancer reveals unique alterations involving telomerase

An international scientific collaboration has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer, providing new insights not only into this rare cancer but other types as well.

Double mastectomy rates are up, but survival is not improved

The percentage of women that underwent a double mastectomy increased substantially between 1998 and 2011, even though the procedure was not associated with a lower risk of death than breast-conserving surgery plus radiation.